0001104659-24-008862.txt : 20240131
0001104659-24-008862.hdr.sgml : 20240131
20240131165601
ACCESSION NUMBER: 0001104659-24-008862
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240129
FILED AS OF DATE: 20240131
DATE AS OF CHANGE: 20240131
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SCHWARTZ BRIAN
CENTRAL INDEX KEY: 0001431322
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50626
FILM NUMBER: 24583723
MAIL ADDRESS:
STREET 1: C/O ARQULE, INC.
STREET 2: 1 WALL STREET, 6TH FLOOR
CITY: BURLINGTON
STATE: MA
ZIP: 01803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cyclacel Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001130166
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 911766850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 CONNELL DRIVE
STREET 2: SUITE 1500
CITY: BERKELEY HEIGHTS
STATE: NJ
ZIP: 07922
BUSINESS PHONE: 908-517-7330
MAIL ADDRESS:
STREET 1: 200 CONNELL DRIVE
STREET 2: SUITE 1500
CITY: BERKELEY HEIGHTS
STATE: NJ
ZIP: 07922
FORMER COMPANY:
FORMER CONFORMED NAME: XCYTE THERAPIES INC
DATE OF NAME CHANGE: 20001218
4
1
tm244773-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-01-29
0
0001130166
Cyclacel Pharmaceuticals, Inc.
CYCC
0001431322
SCHWARTZ BRIAN
C/O CYCLACEL PHARMACEUTICALS, INC.,
200 CONNELL DRIVE, SUITE 1500
BERKELEY HEIGHTS
NJ
07922
1
1
0
0
Interim Chief Medical Officer
0
Common Stock
2024-01-29
4
A
0
12500
0
A
15205
D
Stock Option (right to buy)
2.28
2024-01-29
4
A
0
12500
0
A
2034-01-29
Common Stock
12500
12500
D
Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date.
These securities were granted to Dr. Schwartz in connection with his appointment as interim Chief Medical Officer of Cyclacel Pharmaceuticals, Inc.
The shares underlying the option vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date.
/s/ Brian Schwartz
2024-01-31